A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Inclusion:
Exclusion
CABA, Buenos Aires C1280AEB, Argentina
Capital Federal, Buenos Aires C1426ANZ, Argentina
La Rioja, F5300COE, Argentina
Yvoir, 5530, Belgium
Belo Horizonte, Minas Gerais 30130-090, Brazil
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Hangzhou, Zhejiang 310003, China
Ostrava-Vitkovice, 703 00, Czechia
Shatin, New Territories, Hong Kong
Kashiwa-shi, Chiba 277-8577, Japan
Kurume-shi, Fukuoka 830-0011, Japan
Akashi-shi, Hyōgo 673-8558, Japan
Hirakata-shi, Osaka 573-1191, Japan
Osakasayama-shi, Osaka 589-8511, Japan
Hidaka-shi, Saitama 350-1298, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Chuo-ku, Tokyo 104-0045, Japan
Koto-ku, Tokyo 135-8550, Japan
Poznan, 60-569, Poland
Matosinhos Municipality, 4464-513, Portugal
Cheongju Chungbuk, 28644, South Korea
Goyang-si Gyeonggi-do, 10408, South Korea
Seongnam-si, Gyeonggi-do, 13620, South Korea
L'Hospitalet de Llobregat, Catalonia 08908, Spain